Viridian Therapeutics (VRDN) investor relations material

Introduction and purpose

• FDA approved Lumvoa (veligrotug/veligrotug-vvze) as the first treatment for thyroid eye disease (TED) with data for both active and chronic forms, marking the company's first commercial product.

• TED is a rare autoimmune disease causing inflammation and vision impairment.

Details of approval or decision

• Lumvoa received FDA approval under Priority Review and Breakthrough Therapy Designation, supported by two pivotal phase 3 trials (THRIVE and THRIVE-2).

• It is indicated for TED regardless of disease activity or duration, with a dosage of 10 mg/kg IV every three weeks for five infusions over 12 weeks.

• Physicians can prescribe Lumvoa immediately following approval.

Impact on industry and stakeholders

• The TED market is estimated at $2 billion annually, with low market penetration and 6,000–7,000 patients treated each year.

• Launch targets 2,000 core prescribers experienced with anti-IGF-1R infusions, expected to drive rapid uptake.

• Comprehensive patient support program (ViridianCares) established to ensure access and assistance.